Danaher Corp. (DHR)
226.28
-0.85
(-0.37%)
USD |
NYSE |
Dec 05, 16:00
226.28
0.00 (0.00%)
After-Hours: 19:29
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 159.83B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -3.28% |
| Valuation | |
| PE Ratio | 46.57 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 6.718 |
| Price to Book Value | 3.130 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.32 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.3555 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 39.81% |
Profile
| Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC. |
| URL | http://www.danaher.com |
| Investor Relations URL | https://investors.danaher.com/ |
| HQ State/Province | District of Columbia |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Jan. 28, 2026 (est.) |
| Last Earnings Release | Oct. 21, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 26, 2025 |
Ratings
Profile
| Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC. |
| URL | http://www.danaher.com |
| Investor Relations URL | https://investors.danaher.com/ |
| HQ State/Province | District of Columbia |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Jan. 28, 2026 (est.) |
| Last Earnings Release | Oct. 21, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 26, 2025 |